Christopher Bloomstran
Semper Augustus Investments Group
Christopher Bloomstran Sanofi ADR stake
total: 94
Semper Augustus Investments Group SNY trades
- Total transactions:
- 16
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 11
- Held since:
- 2013 Q2 or earlier
- Held for:
- 22+ quarters
- Latest activity:
- 2018 Q4
According to 2026 Q2 report, Christopher Bloomstran doesn't hold any Sanofi ADR (SNY) shares. Semper Augustus Investments Group has held SNY since at least 2013 Q2 with 88,615 shares in our earliest available record. Since at least 2013 Q2, Semper Augustus Investments Group has made 15 more transactions.
When did Christopher Bloomstran sell Sanofi ADR (SNY)?
Christopher Bloomstran sold off the entire Sanofi ADR (SNY) position in 2018 Q4.
Estimated cost basis*
- Weighted AVG buy price:
- $47.98
- Weighted AVG sell price:
- $44.72
Christopher Bloomstran's historical trades in Sanofi ADR
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2018 Q4
|
0.00%
|
$44.67
|
-100% (-123,472)
|
|||
|
2018 Q2
|
3.09%
|
$40.01
|
+18.63% (+19,387)
|
|||
|
2018 Q1
|
2.90%
|
$40.08
|
-1.00% (-1,053)
|
|||
|
2017 Q4
|
3.39%
|
$43.00
|
-0.05% (-50)
|
|||
|
2017 Q2
|
3.87%
|
$47.91
|
-0.07% (-72)
|
|||
|
2017 Q1
|
3.56%
|
$45.25
|
-0.33% (-350)
|
|||
|
2016 Q4
|
3.17%
|
$40.44
|
-0.16% (-164)
|
|||
|
2016 Q3
|
2.93%
|
$38.19
|
+4.17% (+4,235)
|
|||
|
2016 Q2
|
3.08%
|
$41.85
|
+23.30% (+19,189)
|
|||
|
2016 Q1
|
2.37%
|
$40.16
|
-1.05% (-870)
|
|||
|
2015 Q3
|
2.77%
|
$47.46
|
-5.43% (-4,780)
|
|||
|
2015 Q2
|
2.92%
|
$49.53
|
-0.16% (-140)
|
|||
|
2014 Q4
|
2.57%
|
$45.61
|
-0.40% (-350)
|
|||
|
2014 Q2
|
2.76%
|
$53.17
|
-0.06% (-50)
|
|||
|
2013 Q4
|
2.70%
|
$53.63
|
-0.08% (-75)
|
|||
|
2013 Q2
|
2.69%
|
$51.51
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.